Records 1-5 (of 5 Records) |
Query Trace: DHODH[original query] |
---|
Human/SARS-CoV-2 Genome-Scale Metabolic Modeling to Discover Potential Antiviral Targets for COVID-19. Wang Feng-Sheng, et al. Journal of the Taiwan Institute of Chemical Engineers 2022 0 0. 104273 |
N4-hydroxycytidine and inhibitors of dihydroorotate dehydrogenase synergistically suppress SARS-CoV-2 replication Stegmann, Kim M et al. bioRxiv June 28 2021 |
Efficacy and safety of Dihydroorotate dehydrogenase (DHODH) inhibitors "Leflunomide" and "Teriflunomide" in Covid-19: A narrative review. Kaur Hardeep, et al. European journal of pharmacology 2021 0 0. 174233 |
Multi-omics study revealing tissue-dependent putative mechanisms of SARS-CoV-2 drug targets on viral infections and complex diseases Zheng, Jie et al. medRxiv May 11 2020 |
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Xiong Rui, et al. Protein & cell 2020 8 0. |
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 25, 2024
- Content source: